Abstract
This brand new market analysis by visiongain examines the prospects for
antibacterial drugs from 2008-2013, including sales forecasts for leading
pharmaceutical products. The antibacterial market is large in terms of disease
area as well as the different drug classes used to treat these infections.
However, this market is entering into a crucial period with many key products
losing patent protection, facing heavy generic competition. In the light of
this, including other factors, visiongain predicts this market to decline in
revenues - but which products will suffer most? How can you fight this generic
competition? The antibacterial drug market generated revenues of $30274m in
2006 - but what will it be in 2013? Only this brand new report will tell you.
The antibacterial market only contained one blockbuster drug in 2006, this
being Johnson & Johnson' s Levaquin. Visiongain predicts that there will be
room for one more blockbuster drug as Levaquin will lose patent protection.
This detailed report also highlights pipeline developments and important
contemporary issues, especially commercial drivers and restraints.
This report will specifically analyse the world markets for the following
classes of antibacterials:
- Cephalosporins
- Macrolides
- Penicillins
- Fluoroquinolones
- Carbapenems
- Miscellaneous.
The group ' miscellaneous' is an assorted group of antibacterials which
includes the minor classes: the tetracyclines, aminoglycosides, glycopeptides
and sulphonamides plus individual antibacterials such as Zyvox and Vancocin.
The Antibacterial Drug Market Analysis 2008 examines the market critically
through a comprehensive review of available information. Sources include
industrial databases, commercial news, published reports, economic research
and consultation with experts. Visiongain applies financial forecasting,
qualitative analyses and the assessment of unmet needs to provide a
comprehensive market report with detailed analysis and informed opinion.
In particular, The Antibacterial Drug Market concentrates on the following
essential aspects of the market:
- Discussion of the current pharmaceutical market
- Forecast of the worldwide pharmaceutical market from 2008-2013
- Drivers and restraints facing the antibacterial drug market
- Opportunities and threats facing the antibacterial drug market
- Growth of the antibacterial drugs market between 2008-2013
- Commercial prospects for the market-leading drugs, with sales forecasts
from 2008-2013
- Individual forecasts of the leading drug classes from 2008-2013
- The potential of generics manufacturers to penetrate this market
- Pipeline developments with blockbuster potential
- Currently marketed drugs with blockbuster potential
- Discussion of unmet therapeutic needs and relative advantages of products
Why you should buy this report:
- To receive a comprehensive analysis of the prospects for antibacterial
drugs from 2008-2013
- To discover predicted revenues, growth rates and other key metrics for
leading pharmaceutical treatments from 2008-2013
- To determine key activities of leading companies
- To discover "hot" pipeline developments and up-and-coming products
- To determine the forces that influence the market for antibacterial drugs:
- Competitive characteristics of the market
- Drivers
- Restraints
- Strengths, weaknesses, opportunities and threats (SWOT analysis)
- To find out where the market is heading - both technologically and
commercially
View Cart
